Pneumonia Vaccine Does Not Protect Against Heart Attacks or Strokes

PASADENA, Calif. The pneumococcal pneumonia vaccination is not associated with a reduced risk of heart attacks or strokes, according to a Kaiser Permanente study published in the Journal of the American Medical Association.

The five-year prospective cohort study, which followed 84,170 men aged 45 to 69, provides new insights about the association between pneumococcal vaccination and heart attacks and strokes. While previous studies have shown that preventing influenza by vaccination reduces the risk of vascular events, the effect of pneumococcal polysaccharide vaccine on vascular events remains controversial, researchers said.

The U.S. Centers for Disease Control and Prevention recommends the pneumonia vaccine for people older than 65 years, for all adults with decreased disease-fighting ability, chronic illness, sickle cell disease, spleen problems, heart disease, lung disease, asthma, diabetes, alcoholism, liver disease, or kidney disease, and for people who smoke cigarettes.

In this study, researchers used electronic health records to link immunization records, health records and detailed lifestyle surveys from 84,170 ethnically diverse California men as part of the California Men’s Health Study, and followed them for an average of five years.

Based on previous research findings, the general public and some clinicians may perceive that the pneumococcal vaccine might have the effect of protecting against heart attack and stroke, but our study showed no such effect, said study lead author Hung-Fu Tseng, PhD, MPH, a research scientist and epidemiologist with the Kaiser Permanente Department of Research and Evaluation in Pasadena. People should continuously pursue other strategies to reduce their risk of heart attack and stroke.

Tseng suggested two methodological distinctions that may explain the difference between this study and the previous study that had suggested a heart-protective effect of the vaccine: The Kaiser Permanente study ascertained and adjusted in the analysis for factors such as diet, disease history, and lifestyle patterns such as cigarette smoking and physical activity level. The cohort design and timing of the questionnaire process regarding exposure factors and electronic clinical records protected against selection bias and biases related to recall.

While this study indicates the pneumococcal vaccine may not offer protection against heart attack or stroke, individuals who think this vaccine might be appropriate for them should discuss it with their health provider, said study co-author Stephen Van Den Eeden, PhD, a senior investigator with the Kaiser Permanente Division of Research in Oakland, Calif.

This is the latest in a series of Kaiser Permanente studies undertaken to better understand the protective effects of vaccines. Recent published studies found children of parents who refuse vaccinesare nine times more likely to get chickenpox and 23 times more likely to get whooping cough compared to fully immunized children. A study published last year by Dr. Tseng found that herpes zoster, also known as shingles, is very rare among children who have been vaccinated against chicken pox.

The California Men’s Health Study was funded by California Cancer Research Program. Other authors on the study included: Jeff Slezak MS, Virginia P. Quinn, PhD, Lina S. Sy, MPH, and Steven Jacobsen, MD, PhD, from the Kaiser Permanente Department of Research and Evaluation in Pasadena, and Stephen K. Van Den Eeden, PhD from the Kaiser Permanente Division of Research in Oakland.

About the Kaiser Permanente Department of Research and Evaluation
The Department of Research and Evaluation conducts high quality, innovative research into disease etiology, prevention, treatment and care delivery. Investigators conduct epidemiology, health sciences, and behavioral research as well as clinical trials. Areas of interest include diabetes and obesity, cancer, HIV/AIDS, cardiovascular disease, aging and cognition, pregnancy outcomes, women’s and children’s health, quality and safety, and pharmacoepidemiology. Located in Pasadena, Calif., the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general population. Visit

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 8.6 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: